Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|August 2, 2018
- Pharmaceutical Technology-08-02-2018
- Volume 42
- Issue 8
AODD Pump Alternative to Plastic Pumps
The C-Series air-operated double-diaphragm (AODD) pump from Almatec, part of PSG, a Dover company, is an alternative to similar plastic pumps and is suited for almost any pumping application that uses an oscillating pump.
The C-Series air-operated double-diaphragm (AODD) pump from Almatec, part of PSG, a Dover company, is an alternative to similar plastic pumps and is suited for almost any pumping application that uses an oscillating pump.
The design enables the housing parts to be jointly tightened via housing bolts; all bolts are tightened together against a diaphragm-sized ring on each side of the pump. Forces of the housing bolts distribute onto the housing parts evenly, providing a consistent flow of forces that increases bolt torque and improves pump safety, as stated by the company. The design also ensures the suction and discharge ports are available as separate housing parts so that different connection versions are available for easy matching to existing installations.
The pumps feature self-priming and dry run capabilities and do not have mechanical seals, drives, nor rotating parts that cause wear over time, the company reports. Available sizes include C 10 (3/8 in.), C 15 (1/2 in.), and C 25 (1 in.) and achieve flow rates from 1.3–7 m3/h at a maximum discharge pressure of 7 bar (100 psig). The wetted housing parts are made of either abrasion-resistant polyethylene or chemically, almost universally resistant polytetrafluoroethylene. The material of the non-wetted center block is polyethylene or polyethylene conductive.
Articles in this issue
about 8 years ago
Pharmaceuticals in the Environmentabout 8 years ago
E&L Risk Assessment for Biologic Drug Productsabout 8 years ago
Exploring a Modern Control Strategy for Wurster Coatingabout 8 years ago
Key Considerations in Multilayer Tabletingabout 8 years ago
FDA is Not Playing Games with Biosimilarsabout 8 years ago
Increasing API Complexity Drives Demand for Cryogenic Capabilitiesabout 8 years ago
Benchtop Sample Preparation Stationabout 8 years ago
Single-Use Electromagnetic Flow Meterabout 8 years ago
Advanced Paddle Blender for LabsRelated to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
4
What the Olanzapine Depot Approval Means for CMC Teams
5